{"id":"NCT03445650","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)","officialTitle":"A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-18","primaryCompletion":"2020-01-18","completion":"2020-01-18","firstPosted":"2018-02-26","resultsPosted":"2023-02-09","lastUpdate":"2023-02-09"},"enrollment":11,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Sjogren-Larsson Syndrome"],"interventions":[{"type":"DRUG","name":"ADX-102 1% Topical Dermal Cream (reproxalap)","otherNames":[]},{"type":"DRUG","name":"Vehicle of ADX-102 Topical Dermal Cream","otherNames":[]}],"arms":[{"label":"ADX-102 1% Topical Dermal Cream (reproxalap)","type":"EXPERIMENTAL"},{"label":"Vehicle of ADX-102 Topical Dermal Cream","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).","primaryOutcome":{"measure":"Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients","timeFrame":"Efficacy assessment period (Week 1 through Week 24), where Baseline is Day 1.","effectByArm":[{"arm":"ADX-102 1% Topical Dermal Cream","deltaMin":-0.7,"sd":0.22}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Pruritus","Rash","Hordeolum","Eosinophilia","Dermatatitis diaper"]}}